SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease

Published: 20 July 2021

  • Views:

    Views Icon 24827
  • Likes:

    Heart Icon 7
  • episode_image
    14m 38s
    Part 1 | Session 6 Panel Discussion Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle
  • episode_image
    6m 58s
    Part 2 | Session 4 Panel Discussion Andrew JS Coats, Gerasimos Filippatos, Shelley Zieroth, Stefan Anker
  • episode_image
    50m 42s
    Part 3 | Session 2 Discussion Alice Cheng, Andrew JS Coats
  • episode_image
    27m 15s
    Part 5 | Session 3 Discussion Giuseppe Rosano, Gerasimos Filippatos
Average (ratings)
No ratings
Your rating


Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders. 


The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.


In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities.  Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives

SGLT2 Inhibition in Cardiorenal Disease

  • Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
  • Apply findings from clinical trials into clinical practice
  • Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
  • Evaluate the safety and cardiorenal benefits of glucose-lowering agents
  • Implement the new guidelines of the HFA of the ESC in clinical practice

Target Audience

  • Cardiologists
  • Nephrologists
  • Endocrinologists

More from this programme

Part 2

SGLT2 Inhibitors in Heart Failure: A Practical Approach

Part 3

Meet The Expert: Implications for Clinical Practice - Breakout 1

Totality of Evidence for the Cardiorenal Patient - discussion with Alice Cheung and Andrew Coats. Session supported by an unrestricted grant from AstraZeneca

Part 4

Meet The Expert: Implications for Clinical Practice - Breakout 2

SGLT2i and QoL Improvement - discussion with Shelley Zieroth and John Spertus.

Part 5

Meet The Expert: Implications for Clinical Practice - Breakout 3

Age groups and vulnerable patients with Gerasimos Filippatos and Giuseppe Rosano.

Part 7

SGLT2 Inhibitors for Heart Failure: The New Standard of Care

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

Part 8

Meet The Expert: Implications for Clinical Practice - Breakout 4

Early Treatment Initiation in the Hospital Setting - discussion with Marc Petrie and Deepak Bhatt. Session supported by an unrestricted grant from AstraZeneca

Part 9

Meet The Expert: Implications for Clinical Practice - Breakout 5

Managing Patients with Comorbidities (T2D & CKD) - discussion with Paola Fioretto and Katherine Tuttle. Session supported by an unrestricted grant from AstraZeneca

Part 10

Meet The Expert: Implications for Clinical Practice - Breakout 6

Interdisciplinary Collaboration and Care Transitions - discussion with Subodh Verma. Session supported by an unrestricted grant from AstraZeneca

Faculty Biographies

Stefan Anker

Stefan Anker

Professor of Cardiology

Prof Stefan Anker is professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. Prodigious researcher who has authored more than 1,000 articles. He has also won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw, Poland.

Prof Anker has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014. He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access heart failure journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.

Prof Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and…

View full profile
Mark Petrie

Mark Petrie

Professor/Honorary Consultant (Institute of Cardiovascular & Medical Sciences)

Prof Mark Petrie is Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK. Prof Petrie started his studies as an undergraduate at Edinburgh University, before training in cardiology in Glasgow. He worked as a heart failure and interventional cardiologist for many years before transferring to the University of Glasgow in 2016.

Prof Petrie's research interests focus on diabetes and cardiovascular disease in heart failure, structural intervention and revascularization in heart failure, peripartum cardiomyopathy, microvascular disease in heart failure with preserved ejection fraction, postmyocardial infarction cardiac remodeling, iron in heart failure, and cardio-oncology. While Prof Petrie has many research interests, he also takes pleasure in mentoring future high-caliber cardiologists and has supervised many outstanding individuals during their PhDs and MDs.

View full profile